A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression w...

Descripción completa

Detalles Bibliográficos
Autores principales: Clamp, A R, Blackhall, F H, Vasey, P, Soukop, M, Coleman, R, Halbert, G, Robson, L, Jayson, G C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394305/
https://www.ncbi.nlm.nih.gov/pubmed/14520436
http://dx.doi.org/10.1038/sj.bjc.6601285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394305/
https://www.ncbi.nlm.nih.gov/pubmed/14520436
http://dx.doi.org/10.1038/sj.bjc.6601285

Ejemplares similares